Welcome to our dedicated page for Mei Pharma news (Ticker: MEIP), a resource for investors and traders seeking the latest updates and insights on Mei Pharma stock.
Lite Strategy, Inc., formerly MEI Pharma, reports developments tied to its transition from a clinical-stage pharmaceutical issuer into a public-company digital asset treasury business. News has centered on the adoption of Litecoin (LTC) as the company’s primary treasury reserve asset, the completed corporate rebrand and Nasdaq ticker change from MEIP to LITS, and capital actions used to fund the strategy.
Company updates also cover treasury-management relationships, governance changes, and historical MEI Pharma disclosures involving cash preservation, strategic alternatives, and oncology drug candidates such as voruciclib and ME-344.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.